SOLOMER Trademark
Trademark Overview
On Wednesday, April 19, 2023, a trademark application was filed for SOLOMER with the United States Patent and Trademark Office. The USPTO has given the SOLOMER trademark a serial number of 79379687. The federal status of this trademark filing is REGISTERED as of Tuesday, December 3, 2024. This trademark is owned by Elasmogen Ltd. The SOLOMER trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; biological preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; anti-angiogenesis preparations; anti-cancer preparations; anti-inflammatory preparations; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro- intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; antibodies and proteins for medical use; DNA and antibodies and proteins that stimulate cells for medical diagnosis purposes; DNA, antibodies a...
Medical and pharmacological research services; scientific and technological services, namely scientific research, analysis and testing in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; scientific research for medical purposes in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; pharmaceutical research and drug development services; pharmaceutical testing; research and development in the biotechnology field; research and development services in the field of antibodies; biotechnology research services; scientific research in the nature of conducting clinical trials for others; biological research, clinical research and medical research; providing scientific information about the results of clinical trials for pharmaceut...
General Information
| Serial Number | 79379687 |
| Word Mark | SOLOMER |
| Filing Date | Wednesday, April 19, 2023 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, December 3, 2024 |
| Registration Number | 7583015 |
| Registration Date | Tuesday, December 3, 2024 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 1, 2024 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; biological preparations for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders; anti-angiogenesis preparations; anti-cancer preparations; anti-inflammatory preparations; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, physiological disorders, hormonal disorders, inherited disease, single gene disorders, respiratory diseases, gastro- intestinal disorders, circulatory disorders, dermatological conditions, immuno-deficiencies, organ damage, cell proliferation, peripheral neurological disorders, genitourinary disorders, musculoskeletal disorders, and blood disorders; antibodies and proteins for medical use; DNA and antibodies and proteins that stimulate cells for medical diagnosis purposes; DNA, antibodies and proteins for therapeutic use for treatment of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases and eye diseases and disorders |
| Goods and Services | Medical and pharmacological research services; scientific and technological services, namely scientific research, analysis and testing in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; scientific research for medical purposes in the field of cancer, inflammatory diseases, auto-inflammatory diseases, autoimmune diseases, eye diseases and disorders, and intracellular delivery of pharmaceuticals and therapeutics; pharmaceutical research and drug development services; pharmaceutical testing; research and development in the biotechnology field; research and development services in the field of antibodies; biotechnology research services; scientific research in the nature of conducting clinical trials for others; biological research, clinical research and medical research; providing scientific information about the results of clinical trials for pharmaceutical products; research services in the field of diagnostic preparations; scientific laboratory services; custom design and development of biochemical assays; scientific and medical research laboratory services; research and development of new products for others; scientific research and analysis in the field of drug discovery; new product development in the field of pharmaceuticals for others; scientific advisory services, namely, medical advisory services related to pharmaceutical development and testing; scientific research consultancy in the field of cancer research, inflammatory disease research, auto-inflammatory disease research, autoimmune disease research, eye disease and disorder research, and intracellular delivery research of pharmaceuticals and therapeutics; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; consulting services for others in the field of design, planning, and implementation and project management of scientific research and clinical trials; providing scientific research information; technical advisory services relating to scientific and clinical research; provision of technical and scientific information and consultancy in relation to the aforesaid services |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 29, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 29, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Elasmogen Ltd |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Elasmogen Ltd |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Elasmogen Ltd |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
Trademark Events
| Event Date | Event Description |
| Thursday, September 28, 2023 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, September 29, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, October 3, 2023 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, January 17, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, January 17, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, January 18, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, February 1, 2024 | REFUSAL PROCESSED BY MPU |
| Thursday, February 1, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Monday, February 19, 2024 | REFUSAL PROCESSED BY IB |
| Monday, July 29, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, July 29, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, July 29, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, August 27, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, September 11, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, October 1, 2024 | PUBLISHED FOR OPPOSITION |
| Thursday, February 27, 2025 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Thursday, February 27, 2025 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Monday, March 3, 2025 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Friday, March 14, 2025 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Tuesday, December 3, 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, October 1, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 3, 2024 | REGISTERED-PRINCIPAL REGISTER |
